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Receptor tyrosine kinasesOverexpression and poor downregulation of ErbB receptor tyrosine kinases are associated with enhanced
signaling and tumorigenesis. Attenuation of EGF-receptor (EGFR) signaling is mediated by endocytosis and
ubiquitination by the E3-ligase Cbl. En route to lysosomes, but before incorporation of the EGFR into internal
vesicles of MVBs, the EGFR undergoes Usp8-mediated deubiquitination. ErbB2 displays enhanced recycling
back to the cell surface, and therefore we hypothesized that Usp8 is not part of the ErbB2 trafﬁcking pathway.
Here, we demonstrate, in the context of a chimeric EGFR-ErbB2 receptor, that (i) EGF induces pY1091 Cbl
binding site-dependent K63-polyubiquitination of EGFR-ErbB2, (ii) Cbl is tyrosine phosphorylated upon
stimulation of EGFR-ErbB2 wt and Y1091F mutant receptor, (iii) EGF-induced activation of EGFR-ErbB2
induces Usp8 tyrosine phosphorylation, and (iv) ubiquitination of the EGFR-ErbB2 wt and Y1091F mutant is
enhanced upon coexpression of catalytically inactive Usp8-C748A in the presence and absence of EGF. We
further show that Usp8 tyrosine phosphorylation upon stimulation of EGFR-ErbB2 is (a) independent of
Y1091, (b) dependent on Src- and EGFR-ErbB2-kinase activity, (c) enhanced upon coexpression of Usp8-
C748A, and (d) partly dependent on the Microtubule Interacting and Transport (MIT) domain of Usp8. Our
ﬁndings demonstrate that Usp8 is part of the ErbB2 endosomal trafﬁcking pathway.logy, Facultyof Science,Radboud
n, TheNetherlands. Tel.:+3124
an Leeuwen).
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The ErbB family of receptor tyrosine kinases consists of four
members denoted ErbB1 (also known as EGFR), ErbB2, ErbB3 and
ErbB4, that form homo- and heterodimeric complexes upon ligand
binding. ErbB2 is an orphan receptor, which functions by forming
heterodimeric complexes with ligand-bound ErbB receptors, includ-
ing the tyrosine kinase inactive ErbB3 [1]. The ErbB receptors are
critical regulators of normal cellular growth, differentiation and
tissue development in many different organs. While EGFR plays an
essential role during epithelial-cell development [2,3], ErbB2 has
been demonstrated to be important in the developing heart [4],
central [5] and peripheral [6] nervous system and mammary gland
morphogenesis [7]. Besides their role in normal physiology, EGFR,
ErbB2 and ErbB3 are also frequently involved in the formation of
solid tumors and as a consequence the ErbB signaling network is one
of the main targets for anti-tumor therapy in humans [8]. ErbB2
overexpression triggers ligand-independent activation of the kinase
domain and is observed in a large proportion of breast and ovarian
cancers, where it is associated with tumour size, spread of the
tumour, resistance to anti-oestrogen therapy and poor prognosis [9].A humanized monoclonal antibody to the extracellular domain of
ErbB2, Herceptin (trastuzumab), has been approved for clinical use
[10].
Attenuation of ErbB receptor signaling is mediated by the clathrin-
dependent pathway of receptor-mediated endocytosis and subse-
quent sorting of the activated ligand-receptor complex via the
multivesicular body (MVB) pathway to lysosomes for degradation
[11]. Thus, incorporation of ErbB receptors in internal vesicles of MVBs
abrogates the communication with cytoplasmic signaling molecules,
leading to attenuation of signaling. Moreover, uncontrolled ErbB
receptor signaling that results from increased receptor expression,
overexpression of ligands, or activating mutations in the transmem-
brane, tyrosine kinase or cytoplasmic domains is often correlatedwith
decreased ErbB receptor downregulation (removal from the cell
surface) [1].
Most studies on receptor downregulation have been performed on
EGFR. Upon EGF binding, the Cbl family of RING ﬁnger E3-ubiquitin
ligases catalyses the ligand-induced ubiquitination of the EGFR, which
plays an important role in EGFR internalization and lysosomal targeting
[11]. Cbl is recruited to the EGFR, either directly through its tyrosine
kinase binding (TKB) domain to phosphorylated tyrosine residue
pY1045 in the cytoplasmic tail of EGFR or indirectly via Grb2, which
binds to phosphorylated tyrosine residues Y1068 and Y1086 [12]. The
RING ﬁnger of Cbl simultaneously interacts with Ubc4/5 E2-ubiquitin
activating enzymes that transfer the activated ubiquitin to lysine side
chains of the EGFR substrate protein [13]. Ubiquitination can either
exist as mono-, multi- (mono-ubiquitination on multiple lysines) or
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signal for proteasomal degradation, K63-linked polyubiquitination has
been shown to regulate non-proteosomal processes such as DNA repair,
kinase activation, translational regulation and vesicular trafﬁcking [14].
Mono- and multi-ubiquitination has been implicated in ligand-
mediated endocytosis [15,16]. Previous reports demonstrate that the
EGFR is undergoing predominantly mono-, multi- and K63-linked
polyubiquitination [17].
Much less is known about the role of ubiquitination in the
intracellular routing of the other ErbB receptors. Previous studies
have shown that ErbB2, ErbB3 and ErbB4 show impaired ligand-
induced downregulation compared to EGFR [18,19]. On the other
hand, ErbB2 and ErbB4 contain similar Cbl binding sites as EGFR [20–
22]. The impaired downregulation of ErbB2 has been correlated with
poor recruitment into clathrin-coated pits resulting in reduced
internalization [18,19,23,24], impaired lysosomal targeting of the
internalized receptor and enhanced recycling from sorting endo-
somes back to the plasma membrane [25–27]. Moreover, hetero-
dimerization with ErbB2 impairs the downregulation of EGFR [25–
28]. When comparing the molecular structure of EGFR and ErbB2,
impaired downregulation of ErbB2 may result from (i) reduced
recruitment of the clathrin adapter protein AP2μ to drive internal-
ization [19,29,30], (ii) the absence of a dileucine signal in the
cytoplasmic tail of ErbB2 that corresponds to EGFR LL1010/1011
which associates with AP2β to promote lysosomal targeting of the
EGFR [22,31], (iii) the presence of a unique 45 amino-acid insert in
the cytoplasmic tail of ErbB2 [32] and/or (iv) impaired recruitment
of Cbl E3 ligases [33]. Notably, we previously demonstrated that the
replacement of the EGFR Cbl binding site by that of ErbB2 did not
affect Cbl recruitment, receptor-ubiquitination, -degradation,
-downregulation or ligand degradation of EGFR, suggesting that
poor downregulation of ErbB2 is not due to sequence variations in
the Cbl binding site of these receptors [22].
We have previously demonstrated that, following ligand-induced
Cbl-mediated ubiquitination, the EGFR is deubiquitinated before
lysosomal degradation [34]. Indeed, two deubiquitinating (DUB)
enzymes have now been demonstrated to deubiquitinate EGFR prior
to incorporation into internal vesicles of MVBs [14]. AMSH is a
metazoan-speciﬁc JAMM-type DUB that is speciﬁc for K63-linked
polyubiquitin and has been proposed to limit sorting of the EGFR
into the MVB pathway [35–37]. Usp8 is a member of the Ubiquitin
speciﬁc protease (Usp) family that removes K48- and K63-linked
polyubiquitin and has been proposed to recycle ubiquitin from
substrate proteins to reﬁll the cellular ubiquitin pool [38–43]. Both
enzymes bind with their PxxP motif to the SH3 domain of the ESCRT-0
subunit STAM and with their N-terminal MIT domain to ESCRT-III
subunits [14]. Using catalytically inactive dominant negative DUB
enzymes, RNA interference techniques and gene knock-out models, it
has been ﬁrmly established that AMSH and Usp8 deubiquitinate the
EGFR [35–37,39–43]. While some reports suggest that Usp8 inhibits
EGFR degradation [40], we and others demonstrated that Usp8
stimulates EGFR degradation [41,42]. Moreover, we also demonstrat-
ed that Usp8 is tyrosine phosphorylated in an EGFR- and Src kinase-
dependent manner following EGF stimulation [41]. However, the
functional signiﬁcance of Usp8 tyrosine phosphorylation is as yet
unknown.
Given the impaired downregulation of ErbB2, we have investigat-
ed in the present study whether ErbB2 and Usp8 functionally interact.
Using a chimeric EGFR-ErbB2 model system, which can be activated
by EGF and therefore allows a fair comparison between the EGFR and
the orphan ErbB2 receptor, we demonstrate that ErbB2 is regulated by
Cbl-mediated K63-linked polyubiquitination and Usp8-mediated
deubiquitination, similarly to EGFR. Moreover, we show that Usp8
interacts with ErbB2 and is tyrosine phosphorylated in a ErbB2- and
Src kinase-dependent manner, although its tyrosine phosphorylation
is to a lesser extent than in the case of EGFR stimulation.2. Material and methods
2.1. Reagents
The following antibodies were used in these studies: α-EGFR
monoclonal antibody (mAb) 528,α-EGFR polyclonal antibodies (pAb)
1005, α-Cbl mAb C15, α-ErbB2 pAb C18, α-GFP pAb FL (Santa Cruz),
α-EGFR mAb LA22, α-phosphotyrosine mAb 4G10, α-K63 ubiquitin
mAb Apu3 (Upstate Biotechnology), α-FLAG mAb M2, α-ubiquitin
pAb U5379 and α-tubulin (Sigma). Immunoprecipitation of EGFR was
carried out using mAb528, while pAb1005 was used for EGFR
detection on Western blots, unless speciﬁed otherwise. Goat anti-
rabbit (GARPO) and goat anti-mouse (GAMPO) mAbs, both linked to
horseradish peroxidase, were purchased from Signal Transduction
Laboratories. Other reagents used in this study included Sepharose
beads coupled to proteins A and G (Amersham Biosciences),
Turbofect™ (Fermentas), EGF (BD Bioscience), Src Inhibitor I
(Sigma) PP2 Src kinase inhibitor and PD153035 EGFR/ErbB2-tyrosine
kinase inhibitor (Calbiochem). All PCR primers were obtained from
Sigma.
2.2. Recombinant DNA technology and constructs
pcDNA3 EGFR and pcDNA3 EGFR Y1045F were kindly provided by
Dr. Y. Yarden (Weizmann Institute, Israel). Mutations of the EGFR Cbl
binding site were introduced as previously described by us [22]. The
K721A mutation was introduced in pcDNA3 EGFR by PCR-mediated
primer overlap extension using the Eco81I sites. pLTR2 EGFR-ErbB2IC
(denoted here as the EGFR-ErbB2 chimera) [18] was kindly provided
by Dr. P.P. di Fiore (Fondazione Instituto FIRC di OncologiaMoleculare,
Italy). The EGFR-ErbB2 was removed from the LTR2 vector by SauI and
XhoI digestion, and subsequently inserted into SauI–XhoI digested
pcDNA3 EGFR. The Y1091F mutation was introduced in pcDNA3
EGFR-ErbB2 chimera by PCR-mediated primer overlap extension
using the BstEII and XhoI sites. The K733Amutation was introduced in
pcDNA3 EGFR-ErbB2 by PCR-mediated primer overlap extension
using the Eco81I and BstEII sites. pLXSN Neo was obtained from Dr. G.P.
Nolan (Stanford University Medical Center) . The retroviral pLXSN
EGFR construct has been described previously [22]. The EGFR and
pcDNA3 EGFR-ErbB2 constructs containing mutations in the Cbl
binding site were cloned into the modiﬁed pLXSN Neo vector using
VspI and XhoI restriction sites. The pME18S Flag mUsp8 construct
containing the Flag epitope-tagged murine Usp8 cDNA was kindly
provided byDr. N. Kitamura (Tokyo Institute of Technology, Japan) [44].
Construction of the catalytically inactive FlagmUsp8 C748Amutant has
been described previously [41]. Both wild-type and C748A Flag mUsp8
cDNAs were subsequently cloned in frame to the C terminus of EGFP
using the pEGFP C1 vector (Clontech), using XhoI and MfeI restriction
sites. Construction of Usp8 Δ140 was performed by overlap extension
PCR of pEGFP C1 Usp8 wt with a temporarily removed NotI site, and
subsequent cloning using the NotI and Acc65I sites. Primer sequences
are available upon request. All mutations were veriﬁed by DNA
sequencing.
2.3. Cell lines and recombinant protein expression
Parental NIH3T3 cells, kindly provided by Dr. J. Schlessinger (Yale
University, New Haven, CT), and human embryonic kidney cells
(HEK293 cells) were maintained in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 10% newborn calf serum
(NCS; Hyclone). Cells were trypsinized when conﬂuent and seeded
in ﬂasks for regular maintenance. HEK293 cells were transiently
transfected using Turbofect™ according to the manufacturer's
protocol, while NIH3T3 cells were retrovirally infected with (mutant)
EGFR or EGFR-ErbB2 constructs, as previously described for EGFR [22].
Fig. 1. Ligand stimulation couples EGFR-ErbB2 to Cbl-induced K63-linked polyubiqui-
tination. NIH3T3 cells were retrovirally infected with EGFR wt, EGFR Y1045F, EGFR-
ErbB2 or EGFR-ErbB2 Y1091F. A, Infected cells were serum starved overnight and
stimulated for 15 minwith 100 ng/ml EGF.Whole cell lysates (WCL) were used for anti-
Cbl immunoprecipitation (IP) and immunoblot (IB) with the indicated antibodies.
B, Infected cells were serum starved overnight and stimulated for 30 min with 100 ng/
ml EGF.WCLwere used for anti-EGFR IP and IB with the indicated antibodies. C, HEK293
cells were transiently transfected with EGFRwt, EGFR, Y1045F, EGFR-ErbB2wt or EGFR-
ErbB2 Y1091F. Serum-starved cells were EGF-stimulated for 15 min. WCL were used for
anti-EGFR IP and IB with the indicated antibodies. Data are representative of 2–4
experiments.
Fig. 2. Ligand stimulation of EGFR-ErbB2 induces Usp8 tyrosine phosphorylation.
HEK293 cells were transiently transfected with EGFP-Flag-Usp8wt or C748Amutant, as
well as with EGFR or EGFR-ErbB2. Serum-starved cells were EGF-stimulated for 1 h and
WCL were used for anti-ﬂag IP and IB with anti-pTyr and anti-ﬂag antibodies as
indicated. Data are representative of 2 experiments.
460 I.M.J. Meijer, J.E.M. van Leeuwen / Cellular Signalling 23 (2011) 458–4672.4. Cell lysis, immunoprecipitation, immunoblotting and densitometry
Cell lysis, immunoprecipitation, immunoblotting and densitome-
try were performed as described previously by us [22,34,41].
3. Results
3.1. Cbl-mediated ubiquitination of the ErbB2 cytoplasmic tail depends
on Y1091
We previously demonstrated that the replacement of the EGFR Cbl
binding site by that of ErbB2 did neither affect Cbl recruitment,
receptor ubiquitination, degradation and downregulation, nor ligand
degradation, suggesting that the poor downregulation of ErbB2 is not
due to sequence variations in the Cbl binding site of these receptors
[22]. Indeed, it has previously been demonstrated that Cbl is tyrosine
phosphorylated and recruited to ErbB2 pY1091 [45]. Moreover, the
ErbB2 Y1091F mutant showed decreased Cbl binding and ErbB2
ubiquitination [20]. However, little is known about ligand-induced
ErbB2 ubiquitination. To test whether the Cbl binding site in ErbB2 is
essential for Cbl recruitment, Cbl tyrosine phoshorylation and
receptor ubiquitination, we made use of chimeric constructs contain-
ing the extracellular and transmembrane domains of the EGFR and the
ErbB2 cytoplasmic tail. Retroviral cell lines containing such chimeric
EGFR-ErbB2 receptors were generated and expression of chimeric
receptors in retroviral cell lines was veriﬁed by Western blot (Fig. 1A,
4th panel).
To test whether Cbl induces ubiquitination of the EGFR-ErbB2
chimera, serum-starved cells were treated with EGF. As shown in
Fig. 1A (upper panel), Cbl is tyrosine phosphorylated 15 min after EGF
stimulation and coprecipitates with the tyrosine phosphorylated
EGFR-ErbB2 chimera. These data indicate that Cbl is recruited to the
EGFR-ErbB2 chimera upon stimulation, although less efﬁcient than to
EGFR itself (Fig. 1A, upper panel). Mutation of the Cbl binding site in
the EGFR (Y1045F) and the chimeric EGFR-ErbB2 (Y1091F) reduced
but did not completely abrogate EGF-induced Cbl tyrosine phosphor-
ylation and coprecipitation of the ErbB receptor (Fig. 1A, upper panel).
Moreover, as shown in Fig. 1B, the EGFR-ErbB2 chimera displayed
prominent EGF-induced ubiquitination, while mutation of the ErbB2
Cbl binding site (Y1091F) in the context of the EGFR-ErbB2 chimera
almost completely abolished EGF-induced ubiquitination of the ErbB2
cytoplasmic domain. In addition, using K63-linked polyubiquitin
speciﬁc antibodies, we show that both EGFR and EGFR-ErbB2 undergo
ligand-induced K63-linked polyubiquitination which is abolished in
EGFR Y1045F and ErbB2 Y1091F mutant constructs (Fig. 1C). In
contrast, we could not detect any ligand-induced increase in K48-
linked polyubiquitination of either EGFR or EGFR-ErbB2 using K48-
linked polyubiquitin speciﬁc antibodies (results not shown). These
ﬁndings directly show the efﬁcacy of the ErbB2 Cbl binding site in
supporting ligand-induced ErbB2 K63-linked polyubiquitination,
which agrees with our previous ﬁndings that the ErbB2 Cbl binding
site is fully functional when introduced into EGFR [22].
3.2. Usp8 tyrosine phosphorylation upon stimulation of the chimeric
EGFR-ErbB2 is enhanced in catalytically inactive Usp8 C748A mutant
The activity of E3 ligases is counterbalanced by the activity of
deubiquitination enzymes. We previously reported that the deubi-
quitination enzyme Usp8 is tyrosine phosphorylated upon stimula-
tion of EGFR [41]. However, Usp8 is present on endosomal
membranes and since ErbB2 shows efﬁcient recycling from early
endosomes back to the cell surface [25], it is possible that internalized
ErbB2 and Ups8 do not interact within the cell. To address whether
Usp8 is tyrosine phosphorylated upon stimulation of EGFR-ErbB2, we
co-transfected HEK293 cells with EGFR-ErbB2 and EGFP-Flag-Usp8. As
shown in Fig. 2, Usp8 becomes tyrosine phosphorylated upontreatment of EGFR-ErbB2 with EGF, although to a lesser extent than
in EGFR stimulated cells. Moreover, activated EGFR-ErbB2 coprecipi-
tates with tyrosine-phosphorylated Flag-tagged Usp8, demonstrating
that Usp8 binds to this chimeric receptor. This ﬁnding demonstrates
that Usp8 is not only a substrate of ErbB2-induced tyrosine kinase
activity, but also that Usp8 and ErbB2 colocalize inside the cell.
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Usp8 (C748A) displays enhanced binding to activated EGFR, which
has been attributed to substrate-trapping on the endosomal mem-
brane [40,46]. Consistent with this model, our data in Fig. 2 show that
Usp8-C748A displays enhanced tyrosine phosphorylation and in-
creased coprecipitation with the receptor upon EGF stimulation of
both EGFR or EGFR-ErbB2 containing cells. These ﬁndings strongly
suggest that the Usp8-C748A mutant shows enhanced steady state
binding to both EGFR and EGFR-ErbB2 relative to Usp8 wild-type,
which is consistent with the model that the C748A mutation
interferes with dissociation of Ups8 from the ubiquitinated ErbB
receptor.
3.3. Usp8 tyrosine phosphorylation is independent of an intact Cbl
binding site
To determine whether Usp8 tyrosine phosphorylation is critically
dependent on ErbB receptor ubiquitination by Cbl, we analyzed Usp8
tyrosine phosphorylation after EGF stimulation of cells containing the
Cbl binding mutants EGFR-Y1045F and EGFR-ErbB2-Y1091F (Fig. 3A–
D). Quantiﬁcation of the Usp8 tyrosine phosphorylation signal of
three independent experiments indicates that Usp8 wt and its C748A
mutant were similarly tyrosine phosphorylated in cells with ErbB
wild-type or the Cbl binding mutant receptors (Fig. 3C–D), although
the level of Usp8-C748A tyrosine phosphorylation appeared some-
what decreased in the EGFR-Y1045F and EGFR-ErbB2-Y1091 mutants
cells in the experiments shown in Fig. 3A–B. Also the extent of
coprecipitation of in particular Usp8-C748A with the EGFR-Y1045F
and EGFR-ErbB2-Y1091F mutant receptors was slightly decreased inFig. 3. Usp8 tyrosine phosphorylation is independent of an intact Cbl binding site. A and B, H
EGFR wt, EGFR-Y1045F, EGFR-ErbB2 wt or EGFR-ErbB2 Y1091F constructs. Serum-starved ce
IP and IB with the indicated antibodies. C and D, densitometric relative corrected mean pixel
(SEM). Phospho-signal of the IPs in A and Bwere related to the amount of precipitated Usp8 i
representative of 3 experiments.this experiment compared to their wild-type counterparts, but again
this was not conﬁrmed by quantitative densitometric analysis of
multiple experiments (data not shown). Collectively, these data
demonstrate that the Cbl binding site of the wild-type EGFR and the
EGFR-ErbB2 chimera is not required for efﬁcient EGF-induced Usp8
tyrosine phosphorylation or coprecipitation of the ErbB receptors
with Usp8.
3.4. Usp8 tyrosine phosphorylation upon stimulation of EGFR-ErbB2 is
Src- and ErbB2- kinase dependent
The data presented in Figs. 2 and 3 suggest that the mechanism
responsible for EGF-induced Usp8 tyrosine phosphorylation might be
the same for EGFR and ErbB2. Our previous results have shown that
Usp8 tyrosine phosphorylation upon EGF-induced stimulation is EGFR-
and Src- tyrosine kinase dependent [41]. To test whether the kinase
activity of ErbB2 is required for Usp8 tyrosine phosphorylation in EGFR-
ErbB2 containing cells, we used the EGFR/ErbB2-kinase inhibitor
PD153035. As shown in Fig. 4A–B (3rd panel), this inhibitor effectively
blocked EGF-induced tyrosine phosphorylation of both EGFR and ErbB2.
In agreement with our previous observation, Usp8 tyrosine phosphor-
ylation following stimulation of EGFR was completely blocked in the
presence of PD153035 (Fig. 4A, top panel, and 4C). In EGFR-ErbB2
expressing cells, EGF-induced Usp8 tyrosine phosphorylation was even
lower in the presence of PD153035 than the Usp8 tyrosine phosphor-
ylation level observed in unstimulated and mock-treated cells (Fig. 4B,
top panel, and D), which is likely due to the fact that 18 h of serum-
deprivation does not result in complete downregulation of ErbB2 kinase
activity. As expected, coprecipitation of autophosphorylated EGFR andEK293 cells were transfected with EGFP-ﬂag-Usp8 wt or C748A mutant and with either
lls were stimulated for 1 h with 100 ng/ml EGF after whichWCLs were used for anti-ﬂag
values of Usp8 tyrosine phosphorylation plotted as mean±standard error of the mean
n the second panels and normalised to the EGFR/EGF or EGFR-ErbB2/EGF group. Data are
Fig. 4. Usp8 is tyrosine phosphorylated in an EGFR/ErbB2-kinase-dependent manner. A and B, HEK293 cells were transfected with EGFP-ﬂag-Usp8 and either EGFR or EGFR-ErbB2.
Serum-starved cellswere pre-treated for 1 hwith 10 μMPD153035 or DMSO and subsequently stimulated for 1 hwith 100 ng/ml EGF.WCLwere used for anti-ﬂag IP and IBwith the indicated
antibodies. C and D, densitometric relative corrected mean pixel values of Usp8 tyrosine phosphorylation plotted as mean±SEM. Phospho-signal of the IPs in A and B were related to the
amount of precipitated Usp8 in the second panels and normalised to the EGFR/EGF or EGFR-ErbB2/EGF group. E and F, HEK293 cells were transfected with EGFP-ﬂag-Usp8 and with either
EGFR wt, EGFR K721A, EGFR-ErbB2 wt or EGFR-ErbB2 K733A. Serum-starved cells were stimulated for 1 h with 100 ng/ml EGF. WCL were used for anti-ﬂag IP and IB with the indicated
antibodies. Data are representative of 3 experiments.
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kinase inhibitor (Fig. 4A and B, top panel). To provide further evidence
for ErbB kinase-dependent Usp8 tyrosine phosphorylation, we gener-
ated kinase-deadmutants of EGFR and EGFR-ErbB2. Stimulation of EGFR
K721A and EGFR-ErbB2 K733A resulted in complete inhibition of Usp8
tyrosine phosphorylation and abrogated the coprecipitation of the
autophosphorylated EGFR and EGFR-ErbB2 with Usp8 (Fig. 4E–F).
EGFR- and ErbB2-tyrosine kinases activate various downstream
signaling molecules including members of the Src-family of tyrosinekinases [47]. To test whether Src-family tyrosine kinases may be
responsible for Usp8 tyrosine phosphorylation upon stimulation of
EGFR-ErbB2, we used the speciﬁc Src-family kinase inhibitors PP2 and
Src Inhibitor I. Complete inhibition of Usp8 tyrosine phosphorylation
in the presence of PP2 was achieved in both EGFR and EGFR-ErbB2
transfected cells (Fig. 5A–B, top panel, and Fig. 5C–D). To further
support these results, we also used another inhibitor, Src Inhibitor I.
As expected, Src Inhibitor I resulted in complete inhibition of Usp8
tyrosine phoshorylation upon EGFR stimulation, even though EGFR
Fig. 5. Src kinase activity is essential for EGFR-ErbB2-mediated Usp8 tyrosine phosphorylation. A and B, HEK293 cells were transfected with EGFP-ﬂag-Usp8 and either EGFR or EGFR-
ErbB2. Serum-starved cells were pre-treated for 1 h with 5 μM PP2 or DMSO and subsequently stimulated for 1 h with 100 ng/ml EGF. WCL were used for anti-ﬂag IP and IB with the
indicated antibodies. C and D, densitometric relative corrected mean pixel values of Usp8 tyrosine phosphorylation plotted as mean+SEM. Phospho-signal of the IPs in A and Bwere
related to the amount of precipitated Usp8 in the second panels and normalised to the EGFR/EGF or EGF-ErbB2/EGF group. E, HEK293 cells were transfected with EGFP-ﬂag-Usp8 and
EGFR wt. Serum-starved cells were pre-treated for 1 h with Src inhibitor I or DMSO and subsequently stimulated for 1 h with 100 ng/ml EGF. WCL were used for anti-ﬂag IP and IB
with the indicated antibodies. Data are representative of 3 experiments.
463I.M.J. Meijer, J.E.M. van Leeuwen / Cellular Signalling 23 (2011) 458–467phosphorylation remained largely intact (Fig. 5E). These data extend
our previous ﬁndings that Usp8 is tyrosine phosphorylated in an
EGFR- and Src kinase-dependent manner [41] and demonstrate that
Usp8 is a substrate for ErbB2-activated Src-family tyrosine kinases.
3.5. Optimal Usp8 tyrosine phosphorylation is MIT domain dependent
TheMIT (Microtubule Interacting and Transport) domain, which is
located at the N-terminus of Usp8, interacts with Escrt-III CHMPproteins and is important for endosomal recruitment [43]. Further-
more, the MIT domain of Usp8 is required for EGFR degradation [43],
suggesting that this domain is essential for proper Usp8 function.
Given that ErbB receptors are present on endosomal membranes, we
hypothesized that MIT-dependent endosomal recruitment of Usp8 is
required for Usp8 tyrosine phosporylation. In cells expressing either
EGFR (Fig. 6A and C) or EGFR-ErbB2 (Fig. 6B and D), removal of the
MIT domain (Usp8 Δ140) resulted in a decrease of the EGF-induced
Usp8 tyrosine phosphorylation, when compared to Usp8 wt.
Fig. 7. Usp8 deubiquitinates EGFR by an EGF-dependent and -independent mechanism.
HEK293 cells were co-transfected with EGFR wt or Y1045F mutant and either EGFP-
ﬂag-Usp8 wt or C748A mutant. Serum-starved cells were stimulated for 15 min with or
without EGF. WCL were used for anti-EGFR IP and IB with the indicated antibodies. Data
are representative of 3 experiments.
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tyrosine phosphorylation. Nevertheless, our ﬁndings clearly demon-
strate that optimal Usp8 tyrosine phosphorylation requires an intact
Usp8 MIT domain.
3.6. ErbB2 is undergoing deubiquitination by Usp8 in an EGF-dependent
and -independent system
The ﬁndings described above demonstrate that Usp8 is part of the
ErbB2 signaling cascade. We previously showed that overexpression
of the Usp8-C748A mutant strongly enhances accumulation of the
steady state level of ubiquitinated EGFR in the absence of EGF [41]. To
provide evidence that EGFR and EGFR-ErbB2 are substrates for Usp8
deubiquitination activity, we performed an in vivo deubiquitination
assay for which the EGFR wt, EGFR-Y1045F, EGFR-ErbB2 wt or EGFR-
ErbB2-Y1091F receptors were co-transfected with either Usp8 wt or
Usp8-C748A mutant into HEK293 cells. As expected, EGF stimulation
of serum-starved cells resulted in an increased molecular size of EGFR
as a result of ubiquitination, which was largely abolished in the EGFR
Y1045F Cbl binding site mutant (Fig. 7, upper panel, 1st four lanes,
arrow a). Interestingly, coexpression of Usp8-C748A with EGFR in
unstimulated cells led to accumulation of ubiquitinated EGFR isoforms
that migrated at a size above the 170 kDa EGFR band (Fig. 7, upper
panel, 5th lane, arrow b), but clearly below the EGF-induced
ubiquitinated forms of EGFR (arrow a). Moreover, in EGF-stimulated
cells expressing both EGFR and Usp8 C748A, we observed not only a
modest increase in the amount of high MW ubiquitinated EGFR
species (Fig. 7, 6th lane, arrow a), but also a strong increase in the low
MW ubiquitinated EGFR forms (arrow b). The low size ubiquitinated
EGFR isoforms were also detected when Usp8-C748A was coex-Fig. 6. The Usp8 MIT domain is required for optimal EGFR-ErbB2-induced Usp8 tyrosine pho
and either EGFR or EGFR-ErbB2. Serum-starved cells were stimulated for 1 h with 100 ng/
densitometric relative corrected mean pixel values of Usp8 tyrosine phosphorylation plotte
precipitated Usp8 in the second panels and normalised to the EGFR/EGF or EGFR-ErbB2/EGpressedwith the EGFR-Y1045F Cbl binding site mutant (Fig. 7, 7th and
8th lanes, arrow b). It is possible that the former signal (arrow a)
represents highly multi- or polyubiquitinated EGFR forms, whereas
the latter signal (arrow b) represents mono- or oligo-ubiquitinated
EGFR species.
To determine whether these ﬁndings can be extended to the
chimeric EGFR-ErbB2 model system, we performed similar experi-
ments for EGFR-ErbB2 wt and EGFR-ErbB2-Y1091F. EGFR-ErbB2sphorylation. A and B, HEK293 cells were transfected with EGFP-ﬂag-Usp8 wt or Δ140
ml EGF. WCL were used for anti-ﬂag IP and IB with the indicated antibodies. C and D,
d as mean±SEM. Phospho-signal of the IPs in A and B were related to the amount of
F group. Data are representative of 3 experiments.
465I.M.J. Meijer, J.E.M. van Leeuwen / Cellular Signalling 23 (2011) 458–467displayed EGF-induced ubiquitination resulting in a high molecular
size band, while the EGFR-ErbB2- Y1091F Cbl binding site mutant
showed almost no EGF-induced ubiquitination (Fig. 8, 1st four lanes,
arrow a). Coexpression of Usp8-C748A with EGFR-ErbB2 wt only
modestly decreased accumulation of the high molecular size
ubiquitination signal induced by EGF stimulation (Fig. 8, 5th and 6th
lanes, arrow a). This contrasts with the EGFR model system shown in
Fig. 7, where expression of inactive Usp8 resulted in only a modest
increase of high molecular size ubiquitination signal, which suggests
that another enzyme may be involved in deubiquitinating ErbB2
(Fig. 8, arrow a). However, in cells coexpressing Usp8-C748A with
EGFR-ErbB2 wt or EGFR-ErbB2-Y1091F a marked increase in the
intensity of the low MW ubiquitination band was observed in both
EGF-stimulated and -unstimulated cells (Fig. 8, 2nd four lanes, arrow
b). Overall, these data demonstrate that ErbB2 is a substrate for the
Usp8 deubiquitinating enzyme.
In conclusion, our ﬁndings demonstrate that Usp8 removes
ubiquitin not only from the EGFR wt and Y1045F mutant receptor,
but also from both the EGFR-ErbB2 wt and Y1091F mutant receptor in
both ligand-independent and ligand-dependent model systems.
4. Discussion
The results presented in this study demonstrate that the
deubiquitinating enzyme Usp8 is part of the ErbB2 endosomal
trafﬁcking pathway. In the context of a chimeric EGFR-ErbB2 receptor,
we have shown that (i) EGF-induced K63-linked polyubiquitination of
the ErbB2 cytoplasmic tail occurs efﬁciently in a pY1091-dependent
manner, (ii) c-Cbl is efﬁciently tyrosine phosphorylated upon
stimulation of the EGFR-ErbB2 wt and Y1091F mutant, (iii) EGF-
induced activation of the EGFR-ErbB2 chimera induces Usp8 tyrosine
phosphorylation, and (iv) ubiquitination of the EGFR-ErbB2 chimera
(wt and Y1091F) is enhanced upon coexpression of catalytically
inactive Usp8-C748A mutant in both an EGF-dependent and
-independent system. We further show that Usp8 tyrosine phosphor-
ylation upon stimulation of EGFR-ErbB2 is (a) independent of Y1091,
(b) dependent on Src- and ErbB2- kinase activity, (c) enhanced upon
coexpression of catalytically inactive Usp8 C748A, and (d) partly
dependent on theMIT domain of Usp8. Our results are consistent with
the model that ErbB2 is less efﬁciently sorted into the MVB pathway
compared to the EGFR.
Here, we demonstrate that c-Cbl is tyrosine phosphorylated and
recruited to the ligand stimulated chimeric EGFR-ErbB2 receptor,Fig. 8. Usp8 deubiquitinates EGFR-ErbB2 by an EGF-dependent and -independent
mechanism. HEK293 cells were co-transfected with EGFR-ErbB2 wt or Y1091F mutant
and either EGFP-ﬂag-Usp8 wt or C748A mutant. Serum-starved cells were stimulated
for 15 min with or without EGF. WCL were used for anti-EGFR IP and IB with the
indicated antibodies. Data are representative of 3 experiments.albeit to a lesser extent than the EGFR (Fig. 1). These results contrast
with those of Levkowitz and coworkers, who initially reported that,
using the same model system, Cbl is not tyrosine phosphorylated and
recruited to ErbB2 [33], Subsequently, these authors demonstrated
that Cbl is recruited to ErbB2 pY1091 of the oncogenic Neu ErbB2
receptor and in wt ErbB2 upon Herceptin-induced crosslinking
[20,21,45]. We have previously reported that the Y1091 Cbl binding
site of ErbB2 can functionally replace the EGFR Y1045 Cbl binding site
without any obvious decrease in Cbl tyrosine phosphorylation, Cbl
recruitment or receptor ubiquitination [22]. Overall, these ﬁndings
suggest that the decreased efﬁciency of steady state Cbl tyrosine
phosphorylation level and steady state Cbl recruitment to ErbB2 is not
primarily due to the inefﬁciency of the ErbB2 Y1091 Cbl binding site,
but rather a consequence of an as yet undeﬁned mechanism that
limits steady state recruitment of Cbl to the ErbB2 receptor. It is
possible that decreased sorting of ErbB2 into theMVB pathway and/or
enhanced recycling of ErbB2 back to the cell surface limits steady state
Cbl-ErbB2 interaction, which may be caused by the presence or
absence of a unique regulatory region in the ErbB2 cytoplasmic tail. As
previously indicated, this may relate to (i) the absence of a dileucine
signal in the cytoplasmic tail of ErbB2 at a position corresponding to
EGFR LL1010/1011, which associates with AP2β to promote lysosomal
targeting [22,31], and (ii) the presence of a unique 45 amino-acid
insert in the cytoplasmic tail of ErbB2 that may be responsible for
enhanced recycling [32]. Regardless of the exact mechanism, our
results demonstrate that ligand stimulation couples ErbB2 to Cbl RING
E3 ligase, resulting in receptor-induced ErbB2 ubiquitination (Fig. 1B).
Furthermore, using K63-linked polyubiquitin speciﬁc antibodies, we
show that EGFR and EGFR-ErbB2 undergo ligand-induced K63
polyubiquitination which is dependent on an intact Cbl binding site.
This result is reminiscent of previous ﬁndings demonstrating that the
EGFR is undergoing predominantly mono-, multi- and K63-linked
polyubiquitination [17] and extends ligand-induced K63-linked
polyubiquitination to ErbB2.
We also showed that Usp8 is coprecipitated and tyrosine
phosphorylated upon EGF stimulation of the EGFR-ErbB2 chimera
(Fig. 2). Interestingly, the Cbl binding site of EGFR-ErbB2 is not
required for Usp8 tyrosine phosphorylation and coprecipitation
(Fig. 3), suggesting that Usp8 might be recruited to the EGFR-ErbB2
also via mechanisms other than interaction between the Usp8 DUB
domain and ubiquitinated cargo (e.g. via Hbp/STAM [44] or the MIT
domain [43]). This ﬁnding extends our previous observations that
Usp8 is tyrosine phosphorylated upon stimulation of the EGFR and
that Usp8 is recruited to the EGFR via multiple interactions including
(direct) binding of the Usp8 DUB domain to ubiquitinated EGFR and
(most likely indirect) recruitment of Usp8 to the EGFR on endosomal
membranes via the Usp8 N-terminal MIT domain [41].
Ligand-induced EGFR-ErbB2-mediated Usp8 tyrosine phosphory-
lation was lower than observed for EGFR. This may be explained by
the fact that ErbB2 displays reduced internalization and enhanced
recycling from early endosomes back to the cell surface when
compared to the EGFR [18,19]. Furthermore, it has been shown that
Usp8 localizes at early endosomes and removes ubiquitin from
proteins after their sorting into the MVB pathway, but before
incorporation of cargo proteins into internal vesicles of MVBs [14].
Thus, our results are consistent with the model that only a relatively
small fraction of Usp8 is subjected to ErbB2-induced tyrosine
phosphorylation because less ErbB2 receptors are sorted into the
MVB pathway. Alternatively, the stoichiometry of ErbB2-induced
Usp8 tyrosine phosphorylationmay be lower than in the case of EGFR.
It has been shown that the enzymatically inactive Usp8-C748A
mutant displays substrate-trapping on the endosomal membrane
[40,42] and consistent with this model, we demonstrated that Usp8
C748A displays enhanced tyrosine phosphorylation (Figs. 2 and 3).
Overall, we showed that Usp8 is a substrate of ErbB2-induced tyrosine
kinase activity.
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that Usp8 tyrosine phosphorylation is dependent on ErbB2- (Fig. 4) and
Src- kinase (Fig. 5) activities, thereby extending our initial ﬁndings in the
EGFR model system to ErbB2 [41]. Src is an SH2- and SH3-domain
containing cytoplasmic tyrosine kinase acting downstream of ErbB
receptors, where it regulates a wide variety of cellular functions. It has
been reported that interaction of tyrosine-phosphorylated ErbB2 in
mammary tumors enhances Src kinase activity [48,49]. Moreover, using
chimeric EGFR-ErbB2 receptors, it has also been shown that Src associates
with ErbB2 [47,50]. We therefore hypothesize that tyrosine phosphory-
lation of Usp8 occurs in an ErbB receptor-Src-Usp8 trimolecular complex.
Our ﬁnding that the MIT domain of Usp8 is essential for optimal
Usp8 tyrosine phosphorylation (Fig. 6) is consistent with the model
that Usp8 is tyrosine phosphorylated upon MIT-dependent recruit-
ment of Usp8 to endosomal membranes. TheMIT domain in Usp8 was
ﬁrst identiﬁed by Row and coworkers, who showed that the MIT
domain interacts with Escrt-III CHMP proteins and is necessary for the
recruitment of Usp8 to endosomal membranes [43]. Although we
cannot exclude the possibility that reduced Usp8 tyrosine phosphor-
ylation upon removal of the MIT domain is due to conformational
effects, we believe this explanation is less likely as this mutant has
been extensively studied before [43]. Interestingly, removal of theMIT
domain does not completely abolish Usp8 tyrosine phosphorylation,
suggesting that Usp8 might be recruited to endosomal membranes
also via alternative mechanisms (e.g. via Hbp/STAM [44] or ubiquitin
[41]). Alternatively, the remaining tyrosine phosphorylation of the
Usp8-Δ140 mutant may also indicate that Usp8 is partly phosphor-
ylated by activated Src-family kinases in the cytoplasm. Finally, it
should also be noted that at present we cannot rule out the possibility
that Usp8 is tyrosine phosphorylated within its MIT domain.
Nevertheless, our ﬁndings demonstrate that optimal Usp8 tyrosine
phosphorylation requires an intact Usp8 MIT domain, which is
consistent with the proposed role of the MIT domain in recruitment
of Usp8 to endosomal membranes where activated ErbB receptor-Src
complexes are located.
Most importantly, our current ﬁndings not only demonstrate that
Usp8 is a substrate for ErbB2-induced tyrosine kinase activity but also
that ErbB2 is a substrate for Usp8-mediated deubiquitination (Fig. 8).
Moreover, overexpression of dominant negative Usp8-C748A led to
enhanced ubiquitination of EGFR and EGFR-ErbB2 under both ligand-
dependent and -independent conditions (Figs. 7 and 8). These
ﬁndings indicate that EGFR and EGFR-ErbB2 are constitutively
ubiquitinated and deubiquitinated. The Cbl binding site mutants of
EGFR (Y1045F) and EGFR-ErbB2 (Y1091F) are also deubiquitinated by
Usp8 both with and without EGF stimulation (Figs. 7 and 8). We
therefore propose that Usp8 is not solely counteracting Cbl-mediated
ubiquitination but also counteracts ligand- and Cbl-independent ErbB
receptor ubiquitination. Our ﬁndings suggest that Usp8 mainly
removes the low molecular size ubiquitination signal from ErbB
receptors and we suggest the possibility that these signals represent
mono- or oligo- ubiquitinated ErbB receptor isoforms (Figs. 7 and 8,
upper panel, arrow b). This hypothesis is supported by our ﬁnding
that EGFRwt and EGFR-ErbB2wt but not their Y1045F and Y1091F Cbl
binding site mutants undergo ligand-induced K63-linked polyubiqui-
tination (Fig. 1). Indeed, the Y1045F and Y1091F Cbl binding site
mutants are deubiquitinated by Usp8, suggesting that this ubiquitina-
tion signal may represent mono- or oligo-ubiquitin (Figs. 7 and 8,
upper panel, arrow b). However, additional studies are required to
verify this hypothesis. Indeed, it has previously been suggested that
Usp8 may disassemble mono- and oligo-ubiquitin chains, in addition
to K63- and K48-linked chains [40,42]. Thus, the role of Usp8 in the
removal of monoubiquitin adducts has not yet been conﬁrmed,
neither in vitro nor in vivo. Our results further suggest that E3 ligases
other than Cbl may be involved in ligand-independent low molecular
size ubiquitination of both EGFR and EGFR-ErbB2. In addition, when
overexpressing inactive Usp8 together with EGFR-ErbB2, a slightdecrease in high molecular size ubiquitin was detected. It is possible
that other DUBs may also be involved in deubiquitination of ErbB2.
5. Conclusions
The results presented in this study demonstrate that (i) Usp8 is a
substrate for ErbB2- and Src-induced tyrosine kinase activity, (ii) EGF
stimulation of the EGFR-ErbB2 chimera results in pY1091 Cbl binding
site-dependent K63-linked polyubiquitination of the ErbB2 cytoplas-
mic tail, and that (iii) ErbB2 is a substrate for Usp8-mediated
deubiquitination.
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